2016 Q4 Form 10-K Financial Statement
#000114420418018690 Filed on April 02, 2018
Income Statement
| Concept | 2016 Q4 | 2016 | 2015 Q4 |
|---|---|---|---|
| Revenue | $15.67M | $44.05M | $10.66M |
| YoY Change | 47.05% | 33.52% | 39.48% |
| Cost Of Revenue | $12.72M | $254.8M | $8.464M |
| YoY Change | 50.24% | 1054.53% | 38.97% |
| Gross Profit | $2.959M | -$210.7M | $2.196M |
| YoY Change | 34.74% | -2029.31% | 41.49% |
| Gross Profit Margin | 18.88% | -478.39% | 20.6% |
| Selling, General & Admin | $4.500M | $18.60M | $3.500M |
| YoY Change | 28.57% | 9.41% | 20.69% |
| % of Gross Profit | 152.08% | 159.37% | |
| Research & Development | |||
| YoY Change | |||
| % of Gross Profit | |||
| Depreciation & Amortization | $148.9K | $18.11M | $145.6K |
| YoY Change | 2.29% | 5316.45% | -24.97% |
| % of Gross Profit | 5.03% | 6.63% | |
| Operating Expenses | $4.700M | $294.2M | $12.12M |
| YoY Change | -61.22% | 773.55% | 32.1% |
| Operating Profit | -$1.741M | $11.69M | -$1.459M |
| YoY Change | 19.29% | -1783.43% | -4.7% |
| Interest Expense | $9.993K | $61.59K | $101.0K |
| YoY Change | -90.1% | -95.36% | -72.18% |
| % of Operating Profit | 0.53% | ||
| Other Income/Expense, Net | $0.00 | $7.148M | -$37.30K |
| YoY Change | -100.0% | -1559.2% | -134.49% |
| Pretax Income | -$1.385M | $18.84M | -$1.497M |
| YoY Change | -7.47% | -1690.67% | 5.16% |
| Income Tax | $99.52K | $8.816M | $36.20K |
| % Of Pretax Income | 46.81% | ||
| Net Earnings | -$1.733M | $11.45M | -$1.686M |
| YoY Change | 2.79% | -735.39% | -0.35% |
| Net Earnings / Revenue | -11.05% | 26.0% | -15.81% |
| Basic Earnings Per Share | $0.46 | -$0.31 | |
| Diluted Earnings Per Share | -$283.3K | $0.41 | -$0.31 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 24.67M shares | 5.366M shares | |
| Diluted Shares Outstanding | 27.97M shares | 5.366M shares |
Balance Sheet
| Concept | 2016 Q4 | 2016 | 2015 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $4.000M | $8.700M | $4.600M |
| YoY Change | -13.04% | -6.45% | -34.29% |
| Cash & Equivalents | $3.989M | $8.700M | $59.01M |
| Short-Term Investments | |||
| Other Short-Term Assets | $500.0K | $300.0K | $400.0K |
| YoY Change | 25.0% | 0.0% | 300.0% |
| Inventory | |||
| Prepaid Expenses | $350.1K | ||
| Receivables | $22.28M | $5.500M | $3.655M |
| Other Receivables | $300.0K | $500.0K | $500.0K |
| Total Short-Term Assets | $81.16M | $14.90M | $9.193M |
| YoY Change | 782.84% | 9.56% | -14.09% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $10.37M | $1.200M | $1.220M |
| YoY Change | 750.35% | 0.0% | 103.31% |
| Goodwill | $103.4M | $100.9M | |
| YoY Change | 2.53% | ||
| Intangibles | $108.1M | $1.237M | |
| YoY Change | 8641.07% | ||
| Long-Term Investments | $24.26M | ||
| YoY Change | |||
| Other Assets | $1.598M | $1.000M | $219.6K |
| YoY Change | 627.52% | 25.0% | -56.07% |
| Total Long-Term Assets | $268.8M | $5.700M | $5.375M |
| YoY Change | 4901.73% | -5.0% | 25.0% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $81.16M | $14.90M | $9.193M |
| Total Long-Term Assets | $268.8M | $5.700M | $5.375M |
| Total Assets | $350.0M | $20.60M | $14.57M |
| YoY Change | 2302.59% | 5.1% | -2.88% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.425M | $7.900M | $3.700M |
| YoY Change | -61.5% | 71.74% | 42.31% |
| Accrued Expenses | |||
| YoY Change | |||
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $400.0K | $4.800M | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $200.0K | $100.0K | $1.200M |
| YoY Change | -83.33% | -50.0% | -25.0% |
| Total Short-Term Liabilities | $50.63M | $14.50M | $6.834M |
| YoY Change | 640.75% | 95.95% | 8.48% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $5.000M | $0.00 |
| YoY Change | -100.0% | ||
| Other Long-Term Liabilities | $800.0K | $700.0K | $2.800M |
| YoY Change | -71.43% | -80.0% | -65.0% |
| Total Long-Term Liabilities | $48.93M | $5.700M | $2.800M |
| YoY Change | 1647.49% | 62.86% | -72.0% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $50.63M | $14.50M | $6.834M |
| Total Long-Term Liabilities | $48.93M | $5.700M | $2.800M |
| Total Liabilities | $11.09M | $21.00M | $9.784M |
| YoY Change | 13.32% | 52.17% | -40.68% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$33.09M | -$24.04M | |
| YoY Change | 37.65% | 31.07% | |
| Common Stock | $6.033K | $5.463K | |
| YoY Change | 10.43% | -88.77% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $87.21M | -$400.0K | -$4.616M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $350.0M | $20.60M | $14.57M |
| YoY Change | 2302.59% | 5.1% | -3.03% |
Cashflow Statement
| Concept | 2016 Q4 | 2016 | 2015 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$1.733M | $11.45M | -$1.686M |
| YoY Change | 2.79% | -735.39% | -0.35% |
| Depreciation, Depletion And Amortization | $148.9K | $18.11M | $145.6K |
| YoY Change | 2.29% | 5316.45% | -24.97% |
| Cash From Operating Activities | $210.0K | $21.91M | -$1.500M |
| YoY Change | -114.0% | -1290.97% | -154.15% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$50.00K | $3.306M | -$130.0K |
| YoY Change | -61.54% | 7328.37% | 550.0% |
| Acquisitions | $0.00 | ||
| YoY Change | -100.0% | ||
| Other Investing Activities | -$240.0K | -$1.090M | $0.00 |
| YoY Change | -5550.0% | -100.0% | |
| Cash From Investing Activities | -$280.0K | -$8.957M | -$130.0K |
| YoY Change | 115.38% | 3482.7% | -81.69% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | $26.66M | ||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | -$10.39M | $10.00M | |
| YoY Change | -2077340.0% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 290.0K | -$17.15M | 2.350M |
| YoY Change | -87.66% | -370.46% | 150.0% |
| NET CHANGE | |||
| Cash From Operating Activities | 210.0K | $21.91M | -1.500M |
| Cash From Investing Activities | -280.0K | -$8.957M | -130.0K |
| Cash From Financing Activities | 290.0K | -$17.15M | 2.350M |
| Net Change In Cash | 220.0K | -$4.190M | 720.0K |
| YoY Change | -69.44% | -198.59% | -76.0% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | $210.0K | $21.91M | -$1.500M |
| Capital Expenditures | -$50.00K | $3.306M | -$130.0K |
| Free Cash Flow | $260.0K | $18.61M | -$1.370M |
| YoY Change | -118.98% | -1087.39% | -149.1% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017 | us-gaap |
Interest Paid Net
InterestPaidNet
|
51043 | USD |
| CY2016Q4 | ameh |
Medical Liabilities Current
MedicalLiabilitiesCurrent
|
18957465 | USD |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
109601999 | USD |
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
50625831 | USD |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3126866 | USD |
| CY2016Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1852144 | USD |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
144159562 | USD |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
81156298 | USD |
| CY2016Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
108094049 | USD |
| CY2016Q4 | us-gaap |
Goodwill
Goodwill
|
103407351 | USD |
| CY2016Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1597978 | USD |
| CY2016Q4 | us-gaap |
Assets
Assets
|
349998962 | USD |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
349998962 | USD |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
490635793 | USD |
| CY2017Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
13279620 | USD |
| CY2016Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
8083277 | USD |
| CY2017Q4 | ameh |
Medical Liabilities Current
MedicalLiabilitiesCurrent
|
63972318 | USD |
| CY2017Q4 | us-gaap |
Minority Interest
MinorityInterest
|
4235398 | USD |
| CY2016Q4 | us-gaap |
Minority Interest
MinorityInterest
|
381617 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
164183426 | USD |
| CY2016Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
87587720 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
24916598 | USD |
| CY2016 | us-gaap |
Cost Of Services
CostOfServices
|
254774585 | USD |
| CY2017 | us-gaap |
Cost Of Services
CostOfServices
|
274656697 | USD |
| CY2016 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
21032971 | USD |
| CY2017 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
26437602 | USD |
| CY2016 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
18114440 | USD |
| CY2017 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
19075353 | USD |
| CY2016 | us-gaap |
Interest Expense
InterestExpense
|
61589 | USD |
| CY2017 | us-gaap |
Interest Expense
InterestExpense
|
79689 | USD |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
18836209 | USD |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
49711113 | USD |
| CY2016 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-1433730 | USD |
| CY2017 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
20022486 | USD |
| CY2017 | us-gaap |
Profit Loss
ProfitLoss
|
45824328 | USD |
| CY2016 | us-gaap |
Profit Loss
ProfitLoss
|
10019797 | USD |
| CY2017 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
14565146 | USD |
| CY2016 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
7147596 | USD |
| CY2016 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
756 | USD |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-14975549 | USD |
| CY2016 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-17147168 | USD |
| CY2017 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
2160736 | USD |
| CY2017 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
1933588 | USD |
| CY2015Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
84499032 | USD |
| CY2016 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
596191 | USD |
| CY2016 | ameh |
Increase Decrease In Medical Liabilities
IncreaseDecreaseInMedicalLiabilities
|
2945946 | USD |
| CY2016 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-8956741 | USD |
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
7970789 | USD |
| CY2016 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
63353 | USD |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-3687022 | USD |
| CY2016 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
1927121 | USD |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
51929379 | USD |
| CY2016 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
21913774 | USD |
| CY2017 | ameh |
Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
|
-1260064 | USD |
| CY2016 | ameh |
Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
|
172311 | USD |
| CY2017 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
-95456 | USD |
| CY2016 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
10903700 | USD |
| CY2017 | ameh |
Finite Lived Intangible Assets Accumulated Amortization Addition
FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition
|
17536700 | USD |
| CY2016 | ameh |
Finite Lived Intangible Assets Accumulated Amortization Addition
FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition
|
16244563 | USD |
| CY2016Q4 | us-gaap |
Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
|
2537703 | USD |
| CY2017Q4 | us-gaap |
Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
|
4343341 | USD |
| CY2016 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
9161855 | USD |
| CY2016 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
2664336 | USD |
| CY2016 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-2199180 | USD |
| CY2016 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-810599 | USD |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.35 | pure |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.06 | pure |
| CY2017 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Concentrations of Risks</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i> </i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company had major payors that contributed the following percentage of net revenue:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> For The Years Ended<br/> December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Payor A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">14.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">14.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Payor B</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">18.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">17.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Payor C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">11.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">12.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Payor D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">11.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">14.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">  <strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company had major payors that contributed to the following percentage of receivables before the allowance for doubtful accounts:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="7"> <div style="CLEAR:both;CLEAR: both"> As of December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="3"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="3"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Payor D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">23.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">37.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Payor E</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">30.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">47.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
87206103 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
159948028 | USD |
| CY2017 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
168102 | USD |
| CY2016 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
233726 | USD |
| CY2016 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
27970431 | shares |
| CY2017 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
44924619 | USD |
| CY2016 | us-gaap |
Net Income Loss
NetIncomeLoss
|
11453527 | USD |
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
25801842 | USD |
| CY2016 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
1722221 | USD |
| CY2017 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
-44886 | USD |
| CY2016 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
11688613 | USD |
| CY2017 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
35145967 | USD |
| CY2016 | us-gaap |
Operating Expenses
OperatingExpenses
|
294246302 | USD |
| CY2017 | us-gaap |
Operating Expenses
OperatingExpenses
|
322601443 | USD |
| CY2017 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
1.01 | |
| CY2016 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.46 | |
| CY2017 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.90 | |
| CY2016 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.41 | |
| CY2017 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
25525786 | shares |
| CY2016 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
24673081 | shares |
| CY2017 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
28661735 | shares |
| CY2016 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-4190135 | USD |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
59014715 | USD |
| CY2017 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
24362223 | USD |
| CY2016 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
29366184 | USD |
| CY2016 | us-gaap |
Interest Paid Net
InterestPaidNet
|
61589 | USD |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
32304876 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
25067953 | shares |
| CY2017Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
18005661 | USD |
| CY2016Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
101132 | USD |
| CY2017Q4 | us-gaap |
Assets Held In Trust Current
AssetsHeldInTrustCurrent
|
2017437 | USD |
| CY2016Q4 | us-gaap |
Assets Held In Trust Current
AssetsHeldInTrustCurrent
|
1050739 | USD |
| CY2017Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1143095 | USD |
| CY2016Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1051807 | USD |
| CY2017Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
20117304 | USD |
| CY2016Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
22275896 | USD |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
13814306 | USD |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
10373333 | USD |
| CY2017Q4 | us-gaap |
Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
|
5000000 | USD |
| CY2016Q4 | us-gaap |
Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
|
5200000 | USD |
| CY2017Q4 | us-gaap |
Loans Receivable Net
LoansReceivableNet
|
10000000 | USD |
| CY2016Q4 | us-gaap |
Loans Receivable Net
LoansReceivableNet
|
0 | USD |
| CY2017Q4 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
21903524 | USD |
| CY2016Q4 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
24256065 | USD |
| CY2017Q4 | us-gaap |
Cost Method Investments
CostMethodInvestments
|
0 | USD |
| CY2016Q4 | us-gaap |
Cost Method Investments
CostMethodInvestments
|
10575002 | USD |
| CY2017Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
745235 | USD |
| CY2016Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
0 | USD |
| CY2017Q4 | us-gaap |
Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
|
0 | USD |
| CY2016Q4 | us-gaap |
Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
|
5338886 | USD |
| CY2017Q4 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
346476231 | USD |
| CY2016Q4 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
268842664 | USD |
| CY2016Q4 | ameh |
Incentive Payable Current
IncentivePayableCurrent
|
19621645 | USD |
| CY2017Q4 | ameh |
Incentive Payable Current
IncentivePayableCurrent
|
21500000 | USD |
| CY2017Q4 | ameh |
Fiduciary Accounts Payable Current
FiduciaryAccountsPayableCurrent
|
2017437 | USD |
| CY2016Q4 | ameh |
Fiduciary Accounts Payable Current
FiduciaryAccountsPayableCurrent
|
1050739 | USD |
| CY2017Q4 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
3198495 | USD |
| CY2016Q4 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
2810357 | USD |
| CY2017Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
98738 | USD |
| CY2016Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
102348 | USD |
| CY2017Q4 | ameh |
Liability For Unissued Equity Shares Noncurrent
LiabilityForUnissuedEquitySharesNoncurrent
|
1185025 | USD |
| CY2016Q4 | ameh |
Liability For Unissued Equity Shares Noncurrent
LiabilityForUnissuedEquitySharesNoncurrent
|
1997650 | USD |
| CY2017Q4 | ameh |
Dividend Payable Noncurrent
DividendPayableNoncurrent
|
18000000 | USD |
| CY2016Q4 | ameh |
Dividend Payable Noncurrent
DividendPayableNoncurrent
|
0 | USD |
| CY2017Q4 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
619001 | USD |
| CY2016Q4 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
0 | USD |
| CY2017Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
44720624 | USD |
| CY2016Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
48929857 | USD |
| CY2017Q4 | us-gaap |
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
|
172129744 | USD |
| CY2016Q4 | us-gaap |
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
|
162855554 | USD |
| CY2017Q4 | us-gaap |
Treasury Stock Common Shares
TreasuryStockCommonShares
|
1682110 | shares |
| CY2016Q4 | us-gaap |
Treasury Stock Common Shares
TreasuryStockCommonShares
|
1682110 | shares |
| CY2017 | us-gaap |
Management Fees Revenue
ManagementFeesRevenue
|
26983695 | USD |
| CY2016 | us-gaap |
Management Fees Revenue
ManagementFeesRevenue
|
24774941 | USD |
| CY2017 | us-gaap |
Other Sales Revenue Net
OtherSalesRevenueNet
|
1531137 | USD |
| CY2016 | us-gaap |
Other Sales Revenue Net
OtherSalesRevenueNet
|
1714939 | USD |
| CY2017 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-1112541 | USD |
| CY2016 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
4748542 | USD |
| CY2016 | us-gaap |
Gain Loss On Sale Of Notes Receivable
GainLossOnSaleOfNotesReceivable
|
0 | USD |
| CY2017 | us-gaap |
Gain Loss On Sale Of Notes Receivable
GainLossOnSaleOfNotesReceivable
|
921938 | USD |
| CY2017 | us-gaap |
Gain Loss On Investments
GainLossOnInvestments
|
13697018 | USD |
| CY2016 | us-gaap |
Gain Loss On Investments
GainLossOnInvestments
|
0 | USD |
| CY2017 | us-gaap |
Health Care Organization Capitation Revenue
HealthCareOrganizationCapitationRevenue
|
272921240 | USD |
| CY2016 | us-gaap |
Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
|
-110000 | USD |
| CY2016 | us-gaap |
Health Care Organization Capitation Revenue
HealthCareOrganizationCapitationRevenue
|
247639181 | USD |
| CY2017 | us-gaap |
Health Care Organization Other Revenue
HealthCareOrganizationOtherRevenue
|
44598373 | USD |
| CY2016 | us-gaap |
Health Care Organization Other Revenue
HealthCareOrganizationOtherRevenue
|
22641884 | USD |
| CY2016 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
107500 | USD |
| CY2017 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
1652286 | USD |
| CY2017 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2059533 | USD |
| CY2016 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
6016850 | USD |
| CY2017 | us-gaap |
Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
|
859430 | USD |
| CY2016 | us-gaap |
Dividends
Dividends
|
20909429 | USD |
| CY2017 | us-gaap |
Dividends
Dividends
|
19697923 | USD |
| CY2016 | us-gaap |
Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
|
5155000 | USD |
| CY2017 | ameh |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Shares
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares
|
1682110 | shares |
| CY2016 | ameh |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Shares
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares
|
1682110 | shares |
| CY2017 | ameh |
Stock Issued During Period Value Merger
StockIssuedDuringPeriodValueMerger
|
64421383 | USD |
| CY2017 | ameh |
Stock Issued During Period Value Conversion Of Liability To Equity
StockIssuedDuringPeriodValueConversionOfLiabilityToEquity
|
1237650 | USD |
| CY2017 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
175000 | USD |
| CY2016 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
320000 | USD |
| CY2017 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
5376215 | USD |
| CY2017Q4 | us-gaap |
Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
|
510391 | USD |
| CY2016Q4 | us-gaap |
Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
|
0 | USD |
| CY2017 | ameh |
Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement
InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement
|
P30Y | |
| CY2015Q4 | us-gaap |
Goodwill
Goodwill
|
100851144 | USD |
| CY2016 | us-gaap |
Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
|
2872817 | USD |
| CY2016 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
316610 | USD |
| CY2017 | us-gaap |
Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
|
86439851 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Next Rolling Twelve Months
OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths
|
3638000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Rolling Year Two
OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo
|
3056000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Rolling Year Three
OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree
|
2523000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Rolling Year Four
OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour
|
1533000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Rolling Year Five
OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive
|
613000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Rolling After Year Five
OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive
|
884000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
12247000 | USD |
| CY2015Q1 | us-gaap |
Capital Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate
CapitalLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate
|
0.03625 | pure |
| CY2016Q1 | ameh |
Lease Commitment
LeaseCommitment
|
1 | USD |
| CY2016Q1 | us-gaap |
Capital Leases Contingent Rental Payments Due
CapitalLeasesContingentRentalPaymentsDue
|
8050 | USD |
| CY2016Q1 | us-gaap |
Capital Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate
CapitalLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate
|
0.03625 | pure |
| CY2015Q1 | ameh |
Lease Commitment
LeaseCommitment
|
1 | USD |
| CY2015Q1 | us-gaap |
Capital Leases Contingent Rental Payments Due
CapitalLeasesContingentRentalPaymentsDue
|
7641 | USD |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
|
75059 | USD |
| CY2017Q4 | us-gaap |
Capital Lease Obligations
CapitalLeaseObligations
|
717739 | USD |
| CY2017Q4 | us-gaap |
Capital Leased Assets Gross
CapitalLeasedAssetsGross
|
750000 | USD |
| CY2017Q4 | us-gaap |
Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
|
53571 | USD |
| CY2017Q4 | us-gaap |
Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
|
696429 | USD |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
|
119000 | USD |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
|
119000 | USD |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
|
119000 | USD |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
|
119000 | USD |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
|
198000 | USD |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
|
793000 | USD |
| CY2017Q3 | us-gaap |
Capital Leases Contingent Rental Payments Due
CapitalLeasesContingentRentalPaymentsDue
|
9910 | USD |
| CY2017Q3 | us-gaap |
Capital Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate
CapitalLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate
|
0.0300 | pure |
| CY2016Q1 | ameh |
Capital Lease Weighted Average Remaining Lease Term
CapitalLeaseWeightedAverageRemainingLeaseTerm
|
P2Y | |
| CY2015Q1 | ameh |
Capital Lease Weighted Average Remaining Lease Term
CapitalLeaseWeightedAverageRemainingLeaseTerm
|
P2Y | |
| CY2017 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
2400000 | USD |
| CY2016 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
2400000 | USD |
| CY2017 | us-gaap |
Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
|
11712965 | USD |
| CY2016 | us-gaap |
Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
|
9163970 | USD |
| CY2017 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
357747410 | USD |
| CY2016 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
305934915 | USD |
| CY2017 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1015204 | USD |
| CY2016 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
504696 | USD |
| CY2017 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
3886785 | USD |
| CY2016 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
8816412 | USD |
| CY2017 | us-gaap |
Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
|
2431791 | USD |
| CY2016 | us-gaap |
Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
|
324306 | USD |
| CY2017 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
86005 | USD |
| CY2016 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
0 | USD |
| CY2017 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2743116 | USD |
| CY2016 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1954238 | USD |
| CY2017 | ameh |
Increasedecrease In Capitation Incentives Payable
IncreasedecreaseInCapitationIncentivesPayable
|
1878355 | USD |
| CY2016 | ameh |
Increasedecrease In Capitation Incentives Payable
IncreasedecreaseInCapitationIncentivesPayable
|
5182665 | USD |
| CY2017 | us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
388138 | USD |
| CY2016 | us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
-17540939 | USD |
| CY2016 | us-gaap |
Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
|
1124320 | USD |
| CY2017 | us-gaap |
Cash Acquired From Acquisition
CashAcquiredFromAcquisition
|
36367555 | USD |
| CY2016 | us-gaap |
Cash Acquired From Acquisition
CashAcquiredFromAcquisition
|
0 | USD |
| CY2017 | us-gaap |
Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
|
-228287 | USD |
| CY2016 | us-gaap |
Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
|
0 | USD |
| CY2017 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
5283 | USD |
| CY2016 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
10447 | USD |
| CY2017 | us-gaap |
Proceeds From Sale Of Loans Receivable
ProceedsFromSaleOfLoansReceivable
|
200000 | USD |
| CY2016 | us-gaap |
Proceeds From Sale Of Loans Receivable
ProceedsFromSaleOfLoansReceivable
|
0 | USD |
| CY2017 | us-gaap |
Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
|
10000000 | USD |
| CY2016 | us-gaap |
Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
|
0 | USD |
| CY2017 | us-gaap |
Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
|
0 | USD |
| CY2016 | us-gaap |
Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
|
200000 | USD |
| CY2017 | us-gaap |
Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
|
1240000 | USD |
| CY2016 | us-gaap |
Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
|
2000000 | USD |
| CY2017 | ameh |
Proceeds From Sale Of Cost Method Investments
ProceedsFromSaleOfCostMethodInvestments
|
25000 | USD |
| CY2016 | ameh |
Proceeds From Sale Of Cost Method Investments
ProceedsFromSaleOfCostMethodInvestments
|
0 | USD |
| CY2017 | ameh |
Payments To Acquire Cost Method Investments
PaymentsToAcquireCostMethodInvestments
|
0 | USD |
| CY2016 | ameh |
Payments To Acquire Cost Method Investments
PaymentsToAcquireCostMethodInvestments
|
5000000 | USD |
| CY2017 | us-gaap |
Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
|
0 | USD |
| CY2016 | us-gaap |
Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
|
2440000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-10702753 | USD |
| CY2016 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-8703162 | USD |
| CY2017 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2084770 | USD |
| CY2016 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3306294 | USD |
| CY2017 | us-gaap |
Increase In Restricted Cash
IncreaseInRestrictedCash
|
18000000 | USD |
| CY2016 | us-gaap |
Increase In Restricted Cash
IncreaseInRestrictedCash
|
0 | USD |
| CY2017 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-20675807 | USD |
| CY2016 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-3009779 | USD |
| CY2017Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
18005661 | USD |
| CY2016Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
101132 | USD |
| CY2017Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
407953 | USD |
| CY2016Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
0 | USD |
| CY2017 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
3175836 | USD |
| CY2016 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
517500 | USD |
| CY2017 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
164797 | USD |
| CY2016 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
260000 | USD |
| CY2017 | ameh |
Proceeds From Stock Options Exercised Included In Liabilities
ProceedsFromStockOptionsExercisedIncludedInLiabilities
|
425025 | USD |
| CY2016 | ameh |
Proceeds From Stock Options Exercised Included In Liabilities
ProceedsFromStockOptionsExercisedIncludedInLiabilities
|
0 | USD |
| CY2017 | us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
102348 | USD |
| CY2016 | us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
181008 | USD |
| CY2017 | us-gaap |
Repayments Of Bank Debt
RepaymentsOfBankDebt
|
0 | USD |
| CY2016 | us-gaap |
Repayments Of Bank Debt
RepaymentsOfBankDebt
|
1477561 | USD |
| CY2017 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-9000000 | USD |
| CY2017 | us-gaap |
Payments Of Dividends
PaymentsOfDividends
|
10447923 | USD |
| CY2016 | us-gaap |
Payments Of Dividends
PaymentsOfDividends
|
26659119 | USD |
| CY2017 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
0 | USD |
| CY2016 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
0 | USD |
| CY2017 | us-gaap |
Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
|
5000000 | USD |
| CY2016 | us-gaap |
Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
|
0 | USD |
| CY2017 | us-gaap |
Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
|
0 | USD |
| CY2016Q4 | ameh |
Subcontractor Ipa Risk Pool Payable
SubcontractorIpaRiskPoolPayable
|
1709112 | USD |
| CY2017Q4 | ameh |
Aca Payable Current
AcaPayableCurrent
|
0 | USD |
| CY2016Q4 | ameh |
Aca Payable Current
AcaPayableCurrent
|
718808 | USD |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
3004215 | USD |
| CY2016Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
411705 | USD |
| CY2017Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
250000 | USD |
| CY2016Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
603041 | USD |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1424573 | USD |
| CY2017Q4 | ameh |
Specialty Capitation Payable Current
SpecialtyCapitationPayableCurrent
|
547307 | USD |
| CY2016Q4 | ameh |
Specialty Capitation Payable Current
SpecialtyCapitationPayableCurrent
|
678335 | USD |
| CY2017Q4 | ameh |
Subcontractor Ipa Risk Pool Payable
SubcontractorIpaRiskPoolPayable
|
1348376 | USD |
| CY2016 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
600000 | USD |
| CY2017 | us-gaap |
Liabilities Assumed1
LiabilitiesAssumed1
|
966698 | USD |
| CY2016 | us-gaap |
Liabilities Assumed1
LiabilitiesAssumed1
|
1313395 | USD |
| CY2017 | us-gaap |
Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
|
5376215 | USD |
| CY2016 | us-gaap |
Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
|
0 | USD |
| CY2017 | us-gaap |
Stock Issued1
StockIssued1
|
0 | USD |
| CY2016 | us-gaap |
Stock Issued1
StockIssued1
|
5155000 | USD |
| CY2017 | ameh |
Deferred Tax Liability Adjusted To Goodwill
DeferredTaxLiabilityAdjustedToGoodwill
|
0 | USD |
| CY2016 | ameh |
Deferred Tax Liability Adjusted To Goodwill
DeferredTaxLiabilityAdjustedToGoodwill
|
977817 | USD |
| CY2017 | ameh |
Equipment Purchased With Capital Lease
EquipmentPurchasedWithCapitalLease
|
0 | USD |
| CY2016 | ameh |
Equipment Purchased With Capital Lease
EquipmentPurchasedWithCapitalLease
|
186092 | USD |
| CY2017 | ameh |
Dividends Declared Included In Dividends Payable And Restricted Cash
DividendsDeclaredIncludedInDividendsPayableAndRestrictedCash
|
18000000 | USD |
| CY2016 | ameh |
Dividends Declared Included In Dividends Payable And Restricted Cash
DividendsDeclaredIncludedInDividendsPayableAndRestrictedCash
|
0 | USD |
| CY2017 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
5294000 | USD |
| CY2017 | ameh |
Reclassification Of Liability For Unissued Common Shares Payable To Equity
ReclassificationOfLiabilityForUnissuedCommonSharesPayableToEquity
|
1237650 | USD |
| CY2016 | ameh |
Reclassification Of Liability For Unissued Common Shares Payable To Equity
ReclassificationOfLiabilityForUnissuedCommonSharesPayableToEquity
|
0 | USD |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3786381 | USD |
| CY2017 | ameh |
Equity Method Investment Significant Influence Description
EquityMethodInvestmentSignificantInfluenceDescription
|
Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. | |
| CY2017Q4 | ameh |
Extendable Amount On Credit Facility
ExtendableAmountOnCreditFacility
|
8000000 | USD |
| CY2017 | ameh |
Percentage Of Managing Responsible Of Health Planship
PercentageOfManagingResponsibleOfHealthPlanship
|
1 | pure |
| CY2017 | ameh |
Term Of Management Service Agreement
TermOfManagementServiceAgreement
|
P10Y | |
| CY2017 | ameh |
Effective Date Of Management Service Agreement
EffectiveDateOfManagementServiceAgreement
|
2017-12-01 | |
| CY2015Q4 | ameh |
Medical Liabilities Current
MedicalLiabilitiesCurrent
|
16011519 | USD |
| CY2017 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
19219251 | USD |
| CY2017 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
5336885 | USD |
| CY2017 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-18718113 | USD |
| CY2017 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-1951238 | USD |
| CY2016 | ameh |
Adjustments For Medical Liabilities
AdjustmentsForMedicalLiabilities
|
3061157 | USD |
| CY2017 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
24556136 | USD |
| CY2016 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
11826191 | USD |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.350 | pure |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.044 | pure |
| CY2017 | ameh |
Effective Income Tax Rate Reconciliation Federal Rate Adjustment
EffectiveIncomeTaxRateReconciliationFederalRateAdjustment
|
-0.097 | pure |
| CY2016 | ameh |
Effective Income Tax Rate Reconciliation Federal Rate Adjustment
EffectiveIncomeTaxRateReconciliationFederalRateAdjustment
|
0.065 | pure |
| CY2017Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
|
-913468 | USD |
| CY2017 | us-gaap |
Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
|
14984000 | USD |
| CY2017 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
3235000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
40942442 | USD |
| CY2017 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1538653 | USD |
| CY2016 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1445877 | USD |
| CY2015Q3 | us-gaap |
Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
|
600000 | USD |
| CY2015Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
129492000 | USD |
| CY2016Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
132727000 | USD |
| CY2016 | us-gaap |
Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
|
3235000 | USD |
| CY2016 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
0 | USD |
| CY2016Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
24632951 | USD |
| CY2017Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
144476000 | USD |
| CY2017 | us-gaap |
Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
|
61092050 | USD |
| CY2017 | us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
85526383 | USD |
| CY2017 | us-gaap |
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
|
6109205 | shares |
| CY2017Q4 | us-gaap |
Business Acquisition Share Price
BusinessAcquisitionSharePrice
|
10.00 | |
| CY2017Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
|
36367555 | USD |
| CY2017Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
|
7261588 | USD |
| CY2017Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
|
3211028 | USD |
| CY2017Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
|
249193 | USD |
| CY2017Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
|
1114332 | USD |
| CY2017Q4 | ameh |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restricted Cash
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash
|
745220 | USD |
| CY2017Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
|
14984000 | USD |
| CY2017Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Assets Noncurrent
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent
|
1387961 | USD |
| CY2017Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
|
217241 | USD |
| CY2017Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
|
65538118 | USD |
| CY2017Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
|
8632893 | USD |
| CY2017Q4 | ameh |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Medical Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities
|
39353540 | USD |
| CY2017Q4 | ameh |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Line Of Credit
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit
|
25000 | USD |
| CY2017Q4 | ameh |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Convertible Note Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable
|
5376215 | USD |
| CY2017Q4 | ameh |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Convertible Note Payable To Related Party
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty
|
9921938 | USD |
| CY2017Q4 | us-gaap |
Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value
BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
|
3142000 | USD |
| CY2017Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
|
66451586 | USD |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0147 | pure |
| CY2016 | ameh |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
|
0.08 | pure |
| CY2016 | us-gaap |
Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
|
358180435 | USD |
| CY2016 | us-gaap |
Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
|
1072357 | USD |
| CY2016 | us-gaap |
Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
|
0.04 | |
| CY2016 | ameh |
Business Acquisition Proforma Weighted Average Common Shares Outstanding Basic
BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic
|
24673081 | shares |
| CY2016 | us-gaap |
Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
|
0.04 | |
| CY2016 | ameh |
Business Acquisition Proforma Weighted Average Common Shares Outstanding Diluted
BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted
|
27970431 | shares |
| CY2017 | ameh |
Payments For Agreement Termination
PaymentsForAgreementTermination
|
400000 | USD |
| CY2017 | us-gaap |
Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
|
478873780 | USD |
| CY2017 | us-gaap |
Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
|
9982706 | USD |
| CY2017 | ameh |
Business Acquisition Proforma Weighted Average Common Shares Outstanding Basic
BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic
|
25525786 | shares |
| CY2017 | us-gaap |
Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
|
0.39 | |
| CY2017 | ameh |
Business Acquisition Proforma Weighted Average Common Shares Outstanding Diluted
BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted
|
28661735 | shares |
| CY2017 | us-gaap |
Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
|
0.35 | |
| CY2017Q4 | us-gaap |
Lines Of Credit Current
LinesOfCreditCurrent
|
5025000 | USD |
| CY2016Q4 | us-gaap |
Lines Of Credit Current
LinesOfCreditCurrent
|
0 | USD |
| CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div style="CLEAR:both;CLEAR: both">1.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Description of Business</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Apollo Medical Holdings, Inc. (“ApolloMed”), entered into an Agreement and Plan of Merger dated as of December 21, 2016 (as amended on March 30, 2017 and October 17, 2017) (the “Merger Agreement”) among ApolloMed, Apollo Acquisition Corp., a California corporation and wholly-owned subsidiary of ApolloMed, (“Merger Subsidiary”), Network Medical Management, Inc. (“NMM”), and Kenneth Sim, M.D., not individually but in his capacity as the representative of the shareholders of NMM (the “Merger”). The Merger closed and became effective on December 8, 2017 (the “Closing”) (see Note 3). As a result of the Merger, NMM is now a wholly-owned subsidiary of ApolloMed and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and control of the Board of ApolloMed. For accounting purposes, the Merger is treated as a “reverse acquisition” and NMM is considered the accounting acquirer and ApolloMed the accounting acquiree. Accordingly, as of the Closing, NMM’s historical results of operations replaced ApolloMed’s historical results of operations for all periods prior to the Merger, and the results of operations of both companies are included in the accompanying consolidated financial statements for all periods following the Merger. Effective as of the Closing, ApolloMed’s board of directors approved a change in ApolloMed’s fiscal year end from March 31 to December 31, to correspond with NMM’s fiscal year end prior to the Merger.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The combined company, following the Merger, together with its affiliated physician groups and consolidated entities (collectively, the “Company”) is a physician-centric integrated population health management company working to provide coordinated, outcomes-based medical care in a cost-effective manner and serves patients in California, the majority of whom are covered by private or public insurance such as Medicare, Medicaid and health maintenance organizations (“HMOs”), with a small portion of our revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company’s physician network consists of primary care physicians, specialist physicians and hospitalists. The Company operates primarily through the following subsidiaries of ApolloMed: NMM, Apollo Medical Management, Inc. (“AMM”), APA ACO, Inc. (“APAACO”) and Apollo Care Connect, Inc. (“Apollo Care Connect”), and their consolidated entities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">NMM was formed in 1994 as a management service organization (“MSO”) for the purposes of providing management services to medical companies and independent practice associations (“IPAs”). The management services cover primarily billing, collection, accounting, administrative, quality assurance, marketing, compliance and education.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Allied Physicians of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California (“APC”) was incorporated on August 17, 1992 for the purpose of arranging health care services as an IPA. APC has contracts with various health maintenance organizations (“HMOs”) or licensed health care service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (“PMPM”) that is to be paid to APC. In return, APC arranges for the delivery of health care services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering health care services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On July 1, 1999, APC entered into an amended and restated management and administrative services agreement with NMM (initial management services agreement was entered into in 1997) for an initial fixed term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30</font> years. In accordance with relevant accounting guidance, APC is determined to be a Variable Interest Entity (“VIE”) as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC’s economic performance through its majority representation of the APC Joint Planning Board; therefore APC is consolidated by NMM. From December 8, 2017 through December 31, 2017, APC had an ownership interest of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.95</font>% in ApolloMed. As of December 31, 2016 and through December 7, 2017, APC had an ownership interest of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6.29</font>% in NMM.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Concourse Diagnostic Surgery Center, LLC (“CDSC”) was formed on March 25, 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California, is organized by a group of highly qualified physicians, and the surgical center utilizes some of the most advanced equipment in Eastern Los Angeles County and San Gabriel Valley. The facility is Medicare Certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. During 2011, APC invested $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">625,000</font> for a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 41.59</font>% ownership in CDSC. Due to capital stock changes in 2016, APC’s ownership percentage in CDSC’s capital stock changed to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 43.80</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 43.43</font>% on May 31, 2016 and July 31, 2016, respectively. CDSC is consolidated as a VIE by APC as it was determined that APC has a controlling financial interest in CDSC and is the primary beneficiary of CDSC.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APC-LSMA was formed on October 15, 2012 as a designated shareholder professional corporation and Dr. Thomas Lam, a shareholder, Chief Executive and Financial Officer of APC and Co-CEO of ApolloMed is a nominee shareholder of APC. APC makes all the investment decisions on behalf of APC-LSMA, funds these investments and receives all the distributions from the investments. APC has the obligation to absorb losses or rights to receive benefits from all the investments made by APC-LSMA. APC-LSMA’s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC who is the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, which includes: The IPA line of business of LaSalle Medical Associates (“LMA”), Pacific Medical Imaging and Oncology Center, Inc. (“PMIOC”), Diagnostic Medical Group (“DMG”) and AHMC International Cancer Center (“ICC”).</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">ICC was formed on September 2, 2010 in the state of California. ICC is a Professional Medical California Corporation and has entered into agreements with organizations such as HMOs, IPAs, medical groups and other purchasers of medical services for the arrangement of services to subscribers or enrollees. On November 15, 2016, APC-LSMA, a holding company of APC, agreed to purchase and acquire from ICC <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% of the aggregate issued and outstanding shares of capital stock of ICC for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font> in cash. Certain requirements to complete the investment transaction was completed in August 2017 and effective on October 31, 2017, ICC was determined to be a VIE of APC and is consolidated by APC as it was determined that APC is the primary beneficiary of ICC through its power and obligation to absorb losses and rights to receive benefits that could potentially be significant to ICC. The results of operations of ICC from October 31, 2017 to December 31, 2017 were de minimis.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Universal Care Acquisition Partners, LLC (“UCAP”), a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% owned subsidiary of APC, was formed on June 4, 2014, for the purpose of holding the investment in Universal Care, Inc. (“UCI”).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APAACO, jointly owned by NMM and AMM, participates in the next generation accountable care organization model (“NGACO Model”) of the Centers for Medicare & Medicaid Services (“CMS”) as of January 2017. The NGACO Model is a new CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. In addition to APAACO, NMM and AMM operated three accountable care organizations (“ACOs”) that participated in the Medicare Shared Savings Program (“MSSP”), the goal of which is to improve the quality of patient care and outcomes through more efficient and coordinated approach among providers. MSSP revenues are uncertain, and, if such amounts are payable by CMS, they will be paid on an annual basis significantly after the time earned, and are contingent on various factors, including achievement of the minimum savings rate for the relevant period. Such payments are earned and made on an “all or nothing” basis.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In 2012, ApolloMed formed an ACO, ApolloMed Accountable Care Organization, Inc. (“ApolloMed ACO”) to participate in the MSSP.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On November 11, 2015, NMM, ACO Acquisition Corporation, and APCN-ACO, A Medical Professional Corp. (“APCN-ACO”) entered into a reorganization agreement whereby ACO Acquisition Corporation, a newly organized entity in which NMM is its sole shareholder, merged with APCN-ACO, effective on January 8, 2016, resulting in APCN-ACO becoming a wholly owned subsidiary of NMM (see Note 3).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On December 18, 2016, NMM, ACO Acquisition Corporation #2, and Allied Physicians ACO, LLC (“AP-ACO”) entered into a reorganization agreement whereby ACO Acquisition Corporation #2, a newly organized entity in which NMM is its sole shareholder, merged into AP-ACO, effective on December 20, 2016, resulting in AP-ACO becoming a wholly owned subsidiary of NMM (see Note 3).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As the Company is transitioning to the NGACO Model, patients and physicians with the three ACOs have substantially been transferred to APAACO. Effective on December 31, 2017, APCN-ACO’s MSSP participation agreement with CMS was terminated. Effective on December 31, 2016, AP-ACO’s MSSP participation agreement with CMS was terminated. Effective on December 31, 2017, ApolloMed ACO’s MSSP participation agreement with CMS was terminated.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, which consist of ApolloMed Hospitalists (“AMH”), a hospitalist company, Southern California Heart Centers (“SCHC”), Bay Area Hospitalist Associates (“BAHA”), a medical corporation, ApolloMed Care Clinic (“ACC”) and AKM Medical Group, Inc. (“AKM”). AMH provides hospitalist, intensivist and physician advisor services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. BAHA operates a hospitalist, intensivist and post-acute care practice with a presence at three acute care hospitals, one long-term acute care hospital and several skilled nursing facilities. ACC and AKM are no longer active to any material extent.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Apollo Care Connect, a wholly-owned subsidiary of ApolloMed, provides a cloud and mobile-based population health management platform that includes digital care plans, a case management module, connectivity with multiple healthcare tracking devices and the ability to integrate with multiple electronic health records to capture clinical data.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">ApolloMed also has a controlling interest in Apollo Palliative Services, LLC (“APS”), which owns two Los Angeles-based companies, Best Choice Hospice Care, LLC (“BCHC”) and Holistic Care Home Health Agency, Inc. (“HCHHA”) and provides palliative care services.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">ApolloMed also operated Pulmonary Critical Care Management, Inc. (“PCCM”) and Verdugo Medical Management, Inc. (“VMM”), which operated as physician practice management companies. PCCM and VMM are no longer active to any material extent.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2017 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i> </i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The preparation of consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (including incurred, but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue, income taxes and valuation of share-based compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2017 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Reclassifications</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported revenue, net income, cash flows or total assets.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P2Y9M | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.5301 | pure |
| CY2017 | ameh |
Class Of Warrant Or Rights Assumed From Merger Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsAssumedFromMergerWeightedAverageRemainingContractualTerm
|
P2Y8M8D | |
| CY2017 | ameh |
Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
|
P5Y | |
| CY2017 | ameh |
Class Of Warrant Or Rights Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm
|
P0Y | |
| CY2017 | ameh |
Class Of Warrant Or Rights Forfeited Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm
|
P0Y | |
| CY2017 | ameh |
Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
|
P3Y8M26D | |
| CY2016Q4 | ameh |
Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
|
USD | |
| CY2017Q4 | ameh |
Class Of Warrants Or Right Assumed Rom Merger Aggregate Intrinsic Value
ClassOfWarrantsOrRightAssumedRomMergerAggregateIntrinsicValue
|
14.94 | USD |
| CY2017Q4 | ameh |
Class Of Warrants Or Right Grant In Period Aggregate Intrinsic Value
ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue
|
13.51 | USD |
| CY2017Q4 | ameh |
Class Of Warrants Or Right Exercises In Period Aggregate Intrinsic Value
ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue
|
0 | USD |
| CY2017 | ameh |
Number Of Warrants Assumed From Merger
NumberOfWarrantsAssumedFromMerger
|
1898541 | shares |
| CY2017 | ameh |
Number Of Warrants Granted
NumberOfWarrantsGranted
|
1750000 | shares |
| CY2017 | ameh |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
0 | shares |
| CY2017 | ameh |
Class Of Warrant Or Right Cancelled In Period
ClassOfWarrantOrRightCancelledInPeriod
|
0 | shares |
| CY2016Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
shares | |
| CY2017Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
9.75 | |
| CY2017 | ameh |
Class Of Warrants Or Right Exercise Price Of Warrants Assumed From Merger
ClassOfWarrantsOrRightExercisePriceOfWarrantsAssumedFromMerger
|
9.06 | |
| CY2017 | ameh |
Class Of Warrants Or Right Exercise Price Of Warrants Grant In Period
ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod
|
10.49 | |
| CY2017 | ameh |
Class Of Warrants Or Right Exercise Price Of Warrants Exercised In Period
ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod
|
0 | |
| CY2017 | ameh |
Class Of Warrants Or Right Exercise Price Of Warrants Forfeited In Period
ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod
|
0 | |
| CY2017Q4 | ameh |
Class Of Warrants Or Right Forfeitures In Period Aggregate Intrinsic Value
ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue
|
0 | USD |
| CY2017Q4 | ameh |
Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
|
14.25 | USD |
| CY2017Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
3648541 | shares |
| CY2017 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.17 | |
| CY2017 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
266000 | shares |
| CY2017Q4 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
1.00 | |
| CY2017 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
266000 | USD |
| CY2016 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
3145000 | shares |
| CY2016Q4 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
1.00 | |
| CY2016 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
3145000 | USD |
| CY2016Q4 | us-gaap |
Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
|
525000 | USD |
| CY2017 | ameh |
Restricted Cash Acquired From Acquisition
RestrictedCashAcquiredFromAcquisition
|
18000000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
16657000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
14480000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
12671000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
10961000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
9448000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
37323000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
101540000 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
|
1001754 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
|
888867 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
1784524 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
1685965 | USD |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.009 | pure |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.0 | pure |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
0.014 | pure |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
0.025 | pure |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
|
0.078 | pure |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
-28626943 | USD |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
|
0.468 | pure |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
-44036361 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
|
1941368 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
|
3669941 | USD |
| CY2017 | ameh |
Adjustments For Medical Liabilities
AdjustmentsForMedicalLiabilities
|
-633386 | USD |
| CY2017Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
21530666 | USD |
| CY2016Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
46932207 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance Noncurrent
DeferredTaxAssetsValuationAllowanceNoncurrent
|
3385932 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance Noncurrent
DeferredTaxAssetsValuationAllowanceNoncurrent
|
0 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
|
185130 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
|
208576 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
|
282913 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
|
0 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
7069776 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
0 | USD |
| CY2017Q4 | ameh |
Deferred Tax Assets Liabilities Property Plant And Equipment
DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
|
-1286452 | USD |
| CY2016Q4 | ameh |
Deferred Tax Assets Liabilities Property Plant And Equipment
DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
|
-2009313 | USD |
| CY2017 | ameh |
Medical Liabilities Added From Merger
MedicalLiabilitiesAddedFromMerger
|
39353540 | USD |
| CY2016 | ameh |
Medical Liabilities Added From Merger
MedicalLiabilitiesAddedFromMerger
|
0 | USD |
| CY2015Q4 | us-gaap |
Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
|
4500000 | USD |
| CY2017 | us-gaap |
Dividends Paidinkind
DividendsPaidinkind
|
8750000 | USD |
| CY2016 | us-gaap |
Dividends Paidinkind
DividendsPaidinkind
|
1250000 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
3385932 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
0 | USD |
| CY2017 | us-gaap |
Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
|
use of the Company's net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. | |
| CY2017 | ameh |
Operating Loss Carryforwards Limitation Rate On Taxable Income
OperatingLossCarryforwardsLimitationRateOnTaxableIncome
|
0.8 | pure |
| CY2017 | ameh |
Increase Decrease In Deferred Tax Assets Due To Change In Enacted Tax Rate
IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate
|
6600000 | USD |
| CY2017 | ameh |
Increase Decrease In Deferred Tax Liabilities Due To Change In Enacted Tax Rate
IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate
|
16300000 | USD |
| CY2017 | us-gaap |
Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
|
9700000 | USD |
| CY2017 | ameh |
Holdback Rate
HoldbackRate
|
0.1 | pure |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
0.019 | pure |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
0.032 | pure |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.029 | pure |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.0 | pure |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0.194 | pure |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
-0.0 | pure |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
25677351 | USD |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
18578095 | USD |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
11863045 | USD |
| CY2016Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
8204762 | USD |
| CY2016Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
48944580 | USD |
| CY2017Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
42374500 | USD |
| CY2016Q4 | us-gaap |
Provision For Loss On Contracts
ProvisionForLossOnContracts
|
0 | USD |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
|
792798 | USD |
| CY2015Q4 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
|
2088889 | USD |
| CY2016 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Purchases
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPurchases
|
1527776 | USD |
| CY2016 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
|
1722221 | USD |
| CY2017 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
|
-44886 | USD |
| CY2016Q4 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
|
5338886 | USD |
| CY2017Q4 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
|
0 | USD |
| CY2017 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet
|
5294000 | USD |
| CY2017 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
|
5294000 | USD |
| CY2016 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
7697 | USD |
| CY2016Q4 | ameh |
Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
|
0 | |
| CY2017 | ameh |
Class Of Warrant Or Right Aquired From Merger Intrinsic Value
ClassOfWarrantOrRightAquiredFromMergerIntrinsicValue
|
0.94 | |
| CY2017 | ameh |
Class Of Warrant Or Right Granted Intrinsic Value
ClassOfWarrantOrRightGrantedIntrinsicValue
|
0 | |
| CY2017 | ameh |
Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
|
0 | |
| CY2017 | ameh |
Class Of Warrant Or Right Cancelled
ClassOfWarrantOrRightCancelled
|
0 | |
| CY2017Q4 | ameh |
Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
|
14.25 | |
| CY2017 | ameh |
Number Of Warrants Acquired From Merger
NumberOfWarrantsAcquiredFromMerger
|
1898541 | shares |
| CY2016 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
0 | USD |
| CY2017Q4 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
135300000 | USD |
| CY2016Q4 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
74200000 | USD |
| CY2017Q4 | us-gaap |
Provision For Loss On Contracts
ProvisionForLossOnContracts
|
0 | USD |
| CY2017 | us-gaap |
Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
|
23075516 | USD |
| CY2016 | us-gaap |
Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
|
14501482 | USD |
| CY2017 | us-gaap |
Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
|
121846375 | USD |
| CY2016 | us-gaap |
Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
|
98906764 | USD |
| CY2017 | us-gaap |
Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
|
92476160 | USD |
| CY2016 | us-gaap |
Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
|
84520493 | USD |
